Article Information
History
- March 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Dave Singh1,
- Maxim Bogus2,
- Valentyn Moskalenko3,
- Robert Lord4,
- Edmund J. Moran5,
- Glenn D. Crater5,*,
- David L. Bourdet5,
- Nathan D. Pfeifer5,
- Jacky Woo5,
- Elad Kaufman5,
- David A. Lombardi5,
- Emily Y. Weng5,
- Tuan Nguyen5,
- Ashley Woodcock4,
- Brett Haumann6 and
- Rajeev Saggar5,#
- 1Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundations Trust, Manchester, UK
- 2Arensia Exploratory Medicine SRL, Timofei Mo□neaga Republican Clinical Hospital, Chi□inău, Moldova
- 3Arensia Exploratory Medicine, LLC, Kyiv City Clinical Hospital #12, Kyiv, Ukraine, Oleksandrivska Kyiv City Clinical Hospital, Kyiv, Ukraine, Brovary Multidisciplinary Clinical Hospital, Brovary, Ukraine
- 4University of Manchester, Manchester University NHS Foundations Trust, Manchester, UK
- 5Theravance Biopharma US, Inc., South San Francisco, CA, USA
- 6Theravance Biopharma UK Limited, London, UK
- ↵#Corresponding author:
Rajeev Saggar, Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA, rsaggar{at}theravance.com
Posted March 12, 2021.
A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1
